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OBJECTIVES The purpose of this study was to investigate in vivo the effects of acute systemic inflammation
on the endogenous fibrinolytic capacity in men.
BACKGROUND Systemic inflammation and endogenous fibrinolysis play a major role in the pathogenesis of
coronary artery disease. Although previous studies have shown impaired endothelium-
dependent vasomotor function, the effects of inflammation on the endothelial release of the
fibrinolytic factor tissue plasminogen activator (t-PA) are unknown.
METHODS In a double-blind randomized placebo-controlled crossover trial, we administered a mild
inflammatory stimulus, Salmonella typhi vaccine, or saline placebo to eight healthy men on
two separate occasions. Six hours after vaccination, blood flow and plasma fibrinolytic
variables were measured in both arms during intrabrachial infusions of bradykinin (40 to
1,000 pmol/min), acetylcholine (5 to 20 g/min), and sodium nitroprusside (2 to 8 g/min).
RESULTS Compared with placebo, the S. typhi vaccination caused a rise in white cell count (11.1  0.5
109/l vs. 7.9  0.8 109/l; p  0.004) and plasma interleukin-6 concentrations (6.9  1.4
pg/ml vs. 1.6  0.4 pg/ml; p  0.01) in addition to a significant augmentation of t-PA
antigen (45  9 ng/100 ml/min at peak dose vs. 24  8 ng/100 ml/min at peak dose; p 
0.016, analysis of variance) and activity (104  15 IU/100 ml/min vs. 54  12 IU/100
ml/min; p  0.006, analysis of variance) release during bradykinin infusion. Forearm blood
flow increased in a dose-dependent manner after bradykinin, acetylcholine and sodium
nitroprusside infusions (p  0.001), but this was unaffected by vaccination.
CONCLUSIONS Our results showed that acute systemic inflammation augmented local forearm t-PA release
in men, which suggests that acute inflammation may invoke a protective response by
enhancing the acute endogenous fibrinolytic capacity in healthy men. Further studies are
needed to clarify whether this response is impaired in patients with cardiovascular
disease. (J Am Coll Cardiol 2003;41:333–9) © 2003 by the American College of
Cardiology Foundation
Atherosclerosis is widely recognized to be an inflammatory
disease process involving dysfunction of the vascular endo-
thelium (1). This dysfunction leads to increased expression
of leukocyte adhesion molecules, reduced anticoagulant
activity and the release of growth factors, inflammatory
mediators, and cytokines. Continued inflammation leads to
leukocyte and monocyte recruitment, arterial damage, and
atherogenesis. Additional cycles of damage cause plaque
expansion and disruption that may lead to angina, crescendo
angina, and acute coronary syndromes.
Recent epidemiological and observational studies have
suggested a link between systemic inflammation and coro-
nary artery disease. Infections by organisms, such as Chla-
mydia pneumoniae and herpes simplex virus type 1, appear to
be associated with an increased risk of cardiovascular mor-
tality (2), and approximately 4% of bacteremic patients will
develop acute myocardial infarction within a month of
infection (3). Increased cardiovascular mortality also is seen
after respiratory tract infections (4), severe illnesses requir-
ing intensive care (5), and surgery (6). Markers of systemic
inflammation, such as C-reactive protein (CRP), serum
amyloid A, interleukin-6 (IL-6), and tumor necrosis factor-
alpha, are elevated in patients with cardiovascular disease and
are associated with an adverse prognosis and recurrent coronary
events (7–10). Moreover, in previously healthy individuals,
elevated plasma CRP and IL-6 concentrations predict the
development of cardiovascular disease (11–13). Indeed, reflect-
ing its anti-inflammatory action, the preventative benefits of
aspirin in reducing cardiovascular risk are proportional to the
plasma CRP concentration (11). These data collectively sug-
gest two patterns of association: a link between chronic
inflammation and the slow process of atherogenesis and an
association between acute systemic inflammation and a tran-
siently increased risk of an acute cardiovascular event.
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The vascular endothelium plays a vital role in the control
of blood flow, hemostasis, fibrinolysis, and inflammation
(14), and impaired endothelial function is implicated in the
pathogenesis of coronary artery disease. Tissue plasminogen
activator (t-PA) is a fibrinolytic factor released from the
endothelium through the translocation of a dynamic intra-
cellular storage pool and regulates the degradation of intra-
vascular fibrin (15). If endogenous fibrinolysis is to be
effective, then the rapid mobilization of t-PA from the
endothelium is essential because thrombus dissolution is
much more effective if t-PA is incorporated during, rather
than after, thrombus formation (16,17). However, in the
presence of pro-inflammatory states or an imbalance in
endogenous fibrinolysis, such microthrombi may propagate,
ultimately leading to arterial occlusion and tissue infarction
(18).
We have previously described an in vivo model to assess
the acute release of t-PA in men (19) and demonstrated an
association between t-PA release and endothelial dysfunc-
tion (20,21). Hingorani et al. (22) also have recently shown
that acute inflammation causes dysfunction of endothelium-
dependent vasodilation in humans. However, there have
been no studies to assess directly the acute local fibrinolytic
capacity after acute inflammation. Therefore, the aim of this
study was to test the hypothesis that the acute fibrinolytic
capacity is altered by a mild systemic inflammatory response
generated by typhoid vaccination.
METHODS
Subjects. Eight healthy nonsmoking men between 20 and
27 years of age participated in the study, which was
undertaken with the approval of the local research ethics
committee and in accordance with the Declaration of
Helsinki. The written informed consent of each subject was
obtained before entry into the study.
All subjects were normotensive without a history of
diabetes mellitus and vascular or coronary artery disease.
None of the subjects had undergone typhoid vaccination in
the previous year or received vasoactive or nonsteroidal
anti-inflammatory drugs in the week before the study. All
subjects abstained from alcohol for 24 h and from food and
caffeine-containing drinks for at least 4 h before each
forearm study. All studies were performed in a quiet,
temperature-controlled room maintained at 22 to 25°C.
Drugs. An inflammatory response was generated with a
typhoid vaccination using Salmonella typhi capsular polysac-
charide vaccine 0.025 mg (Typhim Vi, Aventis Pasteur
MSD, Berkshire, United Kingdom). Pharmaceutical-grade
bradykinin (Clinalfa, La¨ufelfingen, Switzerland), acetylcho-
line (Clinalfa), and sodium nitroprusside (David Bull Lab-
oratories, Faulding, United Kingdom) were administered
after dissolution in saline (0.9%; Baxter Healthcare Ltd.,
Berkshire, United Kingdom). All solutions were freshly
prepared on the day of study.
Hemodynamic measurements. Blood flow was measured
in both forearms by venous occlusion plethysmography
using mercury-in-silastic strain gauges as previously de-
scribed (19–21). Blood pressure was monitored in the
noninfused arm at intervals throughout each study with a
semiautomated noninvasive oscillometric sphygmomanom-
eter (Takeda UA 751, Takeda Medical Inc., Tokyo, Japan).
Blood sampling and assays. Blood was withdrawn simul-
taneously from each arm and collected into acidified buff-
ered citrate (Biopool Stabilyte, Umea˚, Sweden) for t-PA
assays and trisodium citrate, ethylene diamine tetraacetic
acid, and serum bead tubes (Monovette, Sarstedt, Nu¨m-
brecht, Germany) for plasminogen activator inhibitor type 1
(PAI-1), IL-6, and CRP assays, respectively, and kept on
ice before being centrifuged at 2,000g for 30 min at 4°C.
Platelet-free plasma was decanted and stored at 80°C
before assay. Plasma t-PA, PAI-1, IL-6, and CRP concen-
trations were determined using specific enzyme-linked im-
munosorbent assays (Coaliza t-PA and Coaliza PAI-1,
Chromogenix AB, Mo¨lndal, Sweden; Quantikine human
IL-6 immunoassays, R&D Systems, United Kingdom;
C-reactive protein enzyme-linked immunosorbent assay,
Eurogenetics, Belgium, respectively) and plasma t-PA ac-
tivity using a photometric method (Coatest t-PA, Chro-
mogenix AB, Mo¨lndal, Sweden). Hematocrit and white cell
count were determined using an automated Coulter counter
(Beckman-Coulter ACt.8 Coulter Counter, High Wy-
combe, United Kingdom).
Study design. The S. typhi vaccine or saline placebo were
injected into the deltoid muscle of each subject’s dominant
arm at 8:30 AM in a randomized, balanced block, double-
blind crossover manner at least two weeks apart. Previous
reports have indicated that vaccination-induced endothelial
dysfunction is transient and resolves within 32 h (22).
Six hours after vaccination and after a 4-h fast, strain
gauges and cuffs were applied. The brachial artery of each
subject’s nondominant arm was cannulated with a 27-
standard wire gauge steel needle (Cooper’s Needle Works
Ltd., Birmingham, United Kingdom) under 1% lidocaine
(Xylocaine; Astra Pharmaceuticals, Wayne Pennsylvania)
local anesthesia and attached to a 16-gauge epidural catheter
(Portex Ltd., Hythe, United Kingdom). Patency was main-
tained by infusion of saline via a MS2000 syringe infusion
pump (Graesby Medical, Watford, United Kingdom). Ve-
nous 17-gauge cannulae were inserted into large subcuta-
neous veins of the antecubital fossae of both arms. Forearm
blood flow (FBF) was measured every 6 to 10 min. After 30
min of equilibration with saline infusion, intra-arterial
Abbreviations and Acronyms
ANOVA  analysis of variance
CRP  C-reactive protein
FBF  forearm blood flow
IL-6  interleukin-6
PAI-1  plasminogen activator inhibitor type 1
t-PA  tissue-type plasminogen activator
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bradykinin was administered at 40, 200, and 1,000 pmol/
min for 10 min at each dose, acetylcholine at 5, 10, and 20
g/min, and sodium nitroprusside at 2, 4, and 8 g/min for
6 min at each dose. The drugs were separated by 20 min of
saline infusion and administered in a randomized order that
was kept constant for each individual. Venous samples were
taken at baseline and during infusion of each bradykinin
dose but not during sodium nitroprusside or acetylcholine
infusion because they do not affect plasma t-PA or PAI-1
concentrations in this forearm model (19,23). White cell
count, hematocrit, IL-6, and CRP were determined 6 h
after vaccination and hematocrit was repeated at the end of
the forearm study.
Data analysis and statistics. Plethysmographic data were
extracted from the chart data files, and FBF was calculated
for individual venous occlusion cuff inflations by use of a
template spreadsheet (Microsoft Excel 97). Recordings for
the first 60 s after wrist cuff inflation were not used because
of the variability in blood flow this initial inflation causes.
The last five linear plethysmographic recordings in each
3-min measurement period were calculated and averaged for
each arm. The estimated net release of t-PA antigen and
activity was defined previously (19) as the product of the
infused forearm plasma flow (based on the mean hematocrit
and the infused FBF) and the concentration difference
between the infused ([t-PA]inf) and noninfused ([t-
PA]noninf) arms and is shown as follows:
Estimated net t-PA release  FBF  (1  Hct)
 t-PAinf  t-PAnoninf	
The area under the curve (AUC) was calculated for
estimated net t-PA antigen and activity release during
bradykinin infusion.
Data were examined, where appropriate, by analysis of
variance (ANOVA) with repeated measures and two-tailed
paired Student t test using Excel 97 (Microsoft). All results
are expressed as mean  SEM. Statistical significance was
assigned at the 5% level.
RESULTS
Inflammatory response. All subjects remained healthy
throughout the study and reported no localized discomfort
or systemic side effects after vaccination. Compared with
placebo injection, there was a marked elevation in white cell
count (11.1  0.5  109/l vs. 7.9  0.8  109/l; p  0.004,
t test) and plasma IL-6 concentrations (6.9  1.4 pg/ml vs.
1.6  0.4 pg/ml; p  0.01, t test) 6 h after typhoid
vaccination, although serum CRP concentrations (1.8  1.2
g/ml vs. 1.0  0.6 g/ml; p  NS, t test) and temperature
(p  NS, t-test) (Table 1) were unchanged.
Assessment of endothelium-dependent vasomotion.
There were no significant effects of vaccination on heart
rate, blood pressure, or baseline FBF. There were no
significant changes in heart rate, blood pressure, or nonin-
fused FBF during drug infusion on either study day.
Forearm blood flow increased in a dose-dependent manner
during bradykinin, acetylcholine, and sodium nitroprusside
infusions (p  0.001, ANOVA), but there was no change in
the blood flow response after vaccination (p  NS,
ANOVA) (Fig. 1).
Assessment of fibrinolytic activity. After vaccination,
there were no changes in baseline plasma t-PA and PAI-1
antigen concentrations nor plasma t-PA activity concentra-
tion. Compared with the noninfused arm, bradykinin
caused dose-dependent increases in plasma t-PA antigen
and activity (p  0.001 for both, ANOVA) concentrations
in the infused arm that were significantly higher after
vaccination (p  0.03, ANOVA) (Table 2). The S. typhi
vaccination caused a significant augmentation in the net
release of t-PA antigen (45  9 vs. 24  8 ng/100 ml/min
at peak dose; p  0.016, ANOVA) and activity (104  15
vs. 54  12 IU/100 ml/min; p  0.006, ANOVA) during
bradykinin infusion, and a two- to threefold increase in the
AUC for net t-PA antigen (37  12 ng/100 ml/min vs. 13
 9 ng/100 ml/min; p  0.14, t test) and activity (70  12
IU/100 ml/min vs. 36  8 IU/100 ml/min; p  0.037, t
test) release compared with placebo (Fig. 2). Plasma PAI-1
Table 1. Baseline Characteristics
Vaccination Placebo
Temperature (°C) 37.0  0.1 36.9  0.1
Systolic blood pressure (mm Hg) 131  4 129  5
Diastolic blood pressure (mm Hg) 62  3 66  3
Heart rate (beats/min) 57  1 57  2
Hematocrit 0.41  0.01 0.41  0.01
Infused forearm blood flow
(ml/100 ml tissue/min)
3.0  0.6 2.8  0.6
Figure 1. Infused forearm blood flow during bradykinin (circles), acetyl-
choline (triangles), and sodium nitroprusside (squares) infusions in sub-
jects who were administered typhoid vaccination (closed symbols) and
saline placebo (open symbols). Analysis of variance, p  0.001 for all
(dose-response).
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concentrations did not change during bradykinin infusion
(Table 2).
DISCUSSION
We have demonstrated that an acute mild systemic inflam-
matory stimulus causes potentiation of bradykinin-induced
t-PA release. We conclude that acute systemic inflamma-
tion enhances local endothelial t-PA release in men. This
may reflect an adaptive mechanism of the vascular endothe-
lium to augment its fibrinolytic response under circum-
stances of acute inflammation.
Endothelium-dependent vasomotion. We assessed basal
and stimulated FBF after intra-arterial infusions of the
endothelium-dependent vasodilators bradykinin and acetyl-
choline, and the endothelium-independent vasodilator so-
dium nitroprusside 6 to 8 h after vaccination. Bradykinin
and acetylcholine have both been widely used to investigate
the function of vascular endothelium. Impaired arterial
vasodilatory response to endothelium-dependent agonists
has been shown in patients with hypertension (24), diabetes
mellitus (25), and hypercholesterolemia (26). Hingorani et
al. (22) have previously reported that S. typhi vaccinations
generated an inflammatory response that was associated
with a temporary suppression of endothelium-dependent
vasodilation in the forearm circulation of six healthy volun-
teers. Although we applied a similar protocol to their study
and included overlapping doses of both bradykinin and
acetylcholine, we did not replicate their findings of impaired
forearm endothelium-dependent vasodilation after vaccina-
tion at 6 to 8 h (Fig. 1). This discrepancy may be partly
explained by the variability in vasodilatory response with
acetylcholine (27) and the higher maximal vasodilator dose
used in our studies, although we used a larger sample size
and a double-blind, randomized, placebo-controlled, cross-
over trial.
Endogenous fibrinolysis. Tissue plasminogen activator,
the key enzyme in the initiation of fibrinolysis, is synthe-
sized in endothelial cells and stored in small, dense vesicles.
It is secreted both basally and in response to thrombin and
several vasoactive agents through a calcium-dependent and
G protein-coupled pathway (28). The regulated endogenous
release of t-PA plays a major role in the defense against
intravascular thrombosis, especially in the coronary circula-
tion (18). Bradykinin is a vasoactive peptide and potent
stimulant for the acute release of t-PA from the vasculature
(23,29–31) and is produced locally through activation of the
kallikrein-kinin system on the surface of endothelial cells
(32). In the present study, bradykinin-induced t-PA antigen
and activity release were augmented two to threefold after
typhoid vaccination in the absence of systemic hemody-
namic effects (Fig. 2).
The underlying mechanisms for our findings are un-
known. Inflammation is recognized to induce a protective
response towards tissue injury, and it functions as part of
normal host surveillance mechanisms. Various compounds
associated with the inflammatory response, including hista-
mine, thrombin and endotoxin, have been shown to increase
cellular t-PA transcription and expression (33,34). How-
ever, we did not observe an increase in the basal plasma
concentrations of either t-PA or PAI-1. The inflammatory
stimulus, therefore, appears to augment specifically the
storage or acute release of t-PA rather than a generalized
upregulation of protein synthesis and basal secretion. This
may be mediated by pro-inflammatory cytokines, such as
IL-6, that modulate cellular activation, leading to alter-
ations in endothelial function. In particular, molecular and
pharmacologic evidence supports the role of bradykinin B2
receptors in the acute phase of inflammation, and upregu-
lation of B2 receptors may account for the potentiation of
bradykinin-induced t-PA release.
Table 2. Plasma t-PA and PAI-1 Antigen and t-PA Activity/Concentrations
Bradykinin Infusion
(pmol/min)
Typhoid Vaccination Placebo Injection
0 40 200 1,000 0 40 200 1,000
t-PA antigen (ng/ml)
Noninfused arm 2.3  0.3 2.7  0.5 2.9  0.5 3.5  0.5 2.8  0.6 3.2  0.8 3.6  0.7 4.4  0.8
Infused arm 3.0  0.5 3.2  0.5 3.9  0.5 6.7  0.7* 2.8  0.6 3.0  0.7 3.8  0.8 6.1  0.9*
Concentration differences
between forearms
0.7  0.4 0.5  0.4 1.0  0.6 3.3  0.8§ 0.0  0.2 0.1  0.4 0.2  0.3 1.7  0.5§‡
t-PA activity (IU/ml)
Noninfused arm 1.3  0.2 1.4  0.2 1.7  0.2 2.6  0.4 1.1  0.2 1.2  0.2 1.5  0.2 2.5  0.5
Infused arm 1.1  0.2 1.6  0.3 3.3  0.6 9.9  1.2* 1.0  0.2 1.3  0.2 2.5  0.5 6.5  1.3*†
Concentration differences
between forearms
0.2  0.1 0.2  0.1 1.6  0.5 7.4  1.0* 0.1  0.1 0.1  0.1 0.9  0.5 3.9  1.0*‡
PAI antigen (ng/ml)
Noninfused arm 17  4 16  2 15  2 16  3
Infused arm 18  5 14  2 16  3 15  2
Concentration differences
between forearms
1.3  2.4 1.2  1.3 0.4  0.8 0.5  1.7
One-way analysis of variance (ANOVA): *p  0.001, §p  0.01 (dose-response). Two-way ANOVA: †p  0.026, ‡p  0.01 (vaccination vs placebo); p  0.001 for all
(dose-response).
PAI-1  plasminogen activator inhibitor type 1; t-PA  tissue-type plasminogen activator.
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Clinical implications. The augmentation of acute t-PA
release after typhoid vaccination suggests that mild acute
inflammation may induce antithrombotic properties in the
forearm circulation. This may represent an adaptive re-
sponse to inhibit intravascular thrombus deposition under
circumstances of acute vascular inflammation. This obser-
vation is consistent with the increase in endogenous fibri-
nolysis in systemic inflammation induced by experimental
endotoxemia in healthy subjects (35). However, in suscep-
tible individuals, such as those with ischemic heart disease
and chronic inflammation, this adaptive and protective
acute response may fail or become depleted, leading to
thrombus propagation and vessel occlusion. The fibrinolytic
response to acute systemic inflammation in patients with
ischemic heart disease and the influence of anti-
inflammatory therapies, such as aspirin, now needs to be
established. Indeed, recent evidence has suggested that
preventative treatment with aspirin is able to reverse
inflammation-induced endothelial dysfunction (36).
Epidemiologic studies have demonstrated an association
between the risk of future cardiovascular events and both
plasma inflammatory markers (11–13) and fibrinolytic fac-
tors (37). Therefore, the current observations are consistent
with the suggestion that elevated plasma t-PA concentra-
Figure 2. Estimated net release of tissue-type plasminogen activator (t-PA) antigen (solid line) and activity (dotted line) in subjects who were administered
typhoid vaccination (closed circles and bars) and saline placebo (open circles and bars). Lower panel represents area under the curve for the response.
Analysis of variance, *p  0.05; †p  0.006 (vaccination vs. placebo); t test, ‡p  0.05 (vaccination vs. placebo).
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tions may provide a marker of vascular inflammation.
Irrespective of whether these common associations are
partly or wholly explained by inflammation-induced t-PA
release, understanding the regulation of both acute and
chronic t-PA release will have important clinical implica-
tions and may help to develop more effective strategies in
the management of atherosclerotic disease.
Study limitations. There are some limitations to our study.
We administered the typhoid vaccination in the deltoid
muscle of each subject’s dominant arm rather than the
gluteus muscle. However, because blood flow was assessed
in the forearm and intra-arterial vasodilators were adminis-
tered in the contralateral nondominant arm, it would be
highly unlikely that the site of vaccination would have
affected the response in the infused forearm. It would also
have been preferable to assess the vascular responses imme-
diately before and 6 to 8 h after vaccination on the same day.
However, this would require repeated arterial cannulations
within the same day, and we have previously demonstrated
that endothelium-dependent vasodilation and t-PA release
is reproducible when performed at least one week apart
(38,39). The study subjects were healthy and young, and we
acknowledge that the response in older subjects may be
quite different. Finally, we studied peripheral vascular func-
tion; therefore, these findings may not be directly applicable
to other vascular beds. However, endothelial dysfunction is
often a generalized process, and we have previously shown
(21,40) consistent endogenous fibrinolytic responses be-
tween the forearm and coronary circulation.
Conclusions. We have demonstrated that mild inflamma-
tion generated by typhoid vaccination results in a significant
potentiation of bradykinin-induced t-PA release from the
vascular endothelium. Additional studies are now required
to determine the underlying mechanism and to assess the
effects of acute and chronic inflammation on endogenous
fibrinolysis in health and disease.
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